JP6702935B2 - 胃がん診断用のマイクロｒｎａバイオマーカー - Google Patents

胃がん診断用のマイクロｒｎａバイオマーカー Download PDF

Info

Publication number
JP6702935B2
JP6702935B2 JP2017504739A JP2017504739A JP6702935B2 JP 6702935 B2 JP6702935 B2 JP 6702935B2 JP 2017504739 A JP2017504739 A JP 2017504739A JP 2017504739 A JP2017504739 A JP 2017504739A JP 6702935 B2 JP6702935 B2 JP 6702935B2
Authority
JP
Japan
Prior art keywords
mir
mirnas
hsa
mirna
gastric cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525350A (ja
JP2017525350A5 (enExample
Inventor
ヘン−フォン トー
ヘン−フォン トー
リーハン チョウ
リーハン チョウ
ルイヤン ゾウ
ルイヤン ゾウ
カイ グアン イェオー
カイ グアン イェオー
ボク ヤン ソー
ボク ヤン ソー
フェン チュー
フェン チュー
ウェイ ペン ヨン
ウェイ ペン ヨン
Original Assignee
エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ
ナショナル ユニヴァーシティー オブ シンガポール
ナショナル ユニヴァーシティー オブ シンガポール
ナショナル ユニバーシティー ホスピタル （シンガポール） ピーティーイー リミテッド
ナショナル ユニバーシティー ホスピタル （シンガポール） ピーティーイー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ, ナショナル ユニヴァーシティー オブ シンガポール, ナショナル ユニヴァーシティー オブ シンガポール, ナショナル ユニバーシティー ホスピタル （シンガポール） ピーティーイー リミテッド, ナショナル ユニバーシティー ホスピタル （シンガポール） ピーティーイー リミテッド filed Critical エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ
Publication of JP2017525350A publication Critical patent/JP2017525350A/ja
Publication of JP2017525350A5 publication Critical patent/JP2017525350A5/ja
Priority to JP2020081954A priority Critical patent/JP7614735B2/ja
Application granted granted Critical
Publication of JP6702935B2 publication Critical patent/JP6702935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
JP2017504739A 2014-08-07 2015-08-11 胃がん診断用のマイクロｒｎａバイオマーカー Active JP6702935B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020081954A JP7614735B2 (ja) 2014-08-07 2020-05-07 胃がん診断用のマイクロｒｎａバイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201404742W 2014-08-07
SG10201404742W 2014-08-07
PCT/SG2015/050256 WO2016022076A1 (en) 2014-08-07 2015-08-11 Microrna biomarker for the diagnosis of gastric cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020081954A Division JP7614735B2 (ja) 2014-08-07 2020-05-07 胃がん診断用のマイクロｒｎａバイオマーカー

Publications (3)

Publication Number Publication Date
JP2017525350A JP2017525350A (ja) 2017-09-07
JP2017525350A5 JP2017525350A5 (enExample) 2017-10-19
JP6702935B2 true JP6702935B2 (ja) 2020-06-03

Family

ID=55264222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504739A Active JP6702935B2 (ja) 2014-08-07 2015-08-11 胃がん診断用のマイクロｒｎａバイオマーカー
JP2020081954A Active JP7614735B2 (ja) 2014-08-07 2020-05-07 胃がん診断用のマイクロｒｎａバイオマーカー
JP2022144766A Active JP7635186B2 (ja) 2014-08-07 2022-09-12 胃がん診断用のマイクロｒｎａバイオマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020081954A Active JP7614735B2 (ja) 2014-08-07 2020-05-07 胃がん診断用のマイクロｒｎａバイオマーカー
JP2022144766A Active JP7635186B2 (ja) 2014-08-07 2022-09-12 胃がん診断用のマイクロｒｎａバイオマーカー

Country Status (7)

Country Link
US (1) US10767230B2 (enExample)
EP (3) EP4137586A1 (enExample)
JP (3) JP6702935B2 (enExample)
KR (2) KR102604163B1 (enExample)
CN (1) CN107109470B (enExample)
SG (2) SG10202011339RA (enExample)
WO (1) WO2016022076A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011339RA (en) * 2014-08-07 2020-12-30 Agency Science Tech & Res Microrna biomarker for the diagnosis of gastric cancer
CN113186271B (zh) * 2015-05-08 2025-06-17 新加坡科技研究局 用于慢性心力衰竭的诊断和预后的方法
CN106636334B (zh) * 2016-10-09 2020-07-03 山东大学 microRNA标志物组及其在制备检测胃癌淋巴结转移试剂盒中的应用
JP6280997B1 (ja) * 2016-10-31 2018-02-14 株式会社Preferred Networks 疾患の罹患判定装置、疾患の罹患判定方法、疾患の特徴抽出装置及び疾患の特徴抽出方法
CN106755377B (zh) * 2016-12-12 2021-05-25 浙江省中医院 一种胃癌血清学检测鉴定试剂盒及方法
US20200157626A1 (en) * 2017-03-23 2020-05-21 Quadrant Biosciences Inc. Method for diagnosing or monitoring conditions characterized by abnormal temporal variations and method of normalizing epigenetic data to compensate for temporal variations
CL2017002289A1 (es) 2017-09-08 2019-08-16 Univ Pontificia Catolica Chile Método no invasivo de diagnóstico temprano de cáncer gástrico, usando como biomarcador los niveles de metilación de la secuencia de adn del promotor del microrna -335-5p
CN107723366B (zh) * 2017-09-11 2019-10-01 朱伟 一种与贲门癌辅助诊断相关的血清miRNA标志物及其应用
CN107746880B (zh) * 2017-11-01 2018-12-14 健生生物技术有限公司 一种基于RT-qPCR法检测胃癌的试剂盒及其制备方法和应用
CN108611414A (zh) * 2018-04-26 2018-10-02 北京工业大学 新的靶向肿瘤微环境与肺癌干细胞相互作用的miRNA的检测及应用
CN108743617A (zh) * 2018-05-03 2018-11-06 武汉科技大学 miR-15a-5p在提高CAR-T细胞抗肿瘤能力中的应用
KR102627788B1 (ko) * 2018-06-21 2024-01-23 고리츠다이가쿠호징 나고야시리츠다이가쿠 위암 바이오마커 및 그 용도
KR102089559B1 (ko) * 2018-08-31 2020-03-16 차의과학대학교 산학협력단 난소의 fsh에 대한 반응성의 진단 또는 예측용 바이오마커 및 이의 용도
TW202018727A (zh) 2018-11-09 2020-05-16 財團法人工業技術研究院 整體式學習預測方法與系統
CN113454242A (zh) * 2018-12-19 2021-09-28 新加坡科技研究局 使用微小rna诊断胃癌的方法
WO2020132494A2 (en) * 2018-12-21 2020-06-25 Baylor Research Institute Methods for prognosing, diagnosing, and treating gastric cancer
CN110066870B (zh) * 2019-04-12 2021-12-14 江苏省人民医院（南京医科大学第一附属医院） hsa-miR-382-5p在制备诊断视网膜变性疾病的试剂盒中的应用
CN117683885A (zh) * 2019-04-30 2024-03-12 觅瑞实验室私人有限公司 一种检测胃癌的miRNA标志物组合及试剂盒
KR102288359B1 (ko) * 2019-12-06 2021-08-10 주식회사 레피겐엠디 면역력 감소에 의한 질병의 발병 위험 예측용 다중 유전자 마커 및 이를 이용한 질병의 발병 위험 예측 방법
CN111471764B (zh) * 2019-12-27 2023-09-15 陈锦飞 一种用于筛查或辅助诊断胃癌的生物标志物组合及其试剂盒和应用
WO2021149719A1 (ja) * 2020-01-24 2021-07-29 アルプスアルパイン株式会社 ｍｉＲＮＡの発現レベルをがんの指標として用いる方法
CN111471683B (zh) * 2020-04-15 2021-09-07 湖南省科域生物医药科技有限公司 miR-93-5p作为诊断和治疗胃癌标志物的应用
KR102489708B1 (ko) * 2020-09-14 2023-01-18 서울대학교산학협력단 GDF11 유전자의 발현을 조절하는 PCBP2와 microRNA를 함유하는 조성물
CN112226514B (zh) * 2020-11-23 2021-08-03 苏州京脉生物科技有限公司 用于早期胃癌检测的标志物组合、试剂盒及其应用
CN112941185B (zh) * 2021-03-26 2023-06-23 杭州医学院 miR-29a作为标志物在制备恶性间皮瘤检测试剂盒中的应用
CN113151477B (zh) * 2021-05-08 2022-04-15 武汉大学中南医院 用于检测肠癌的miRNA标记物及其应用
CN113186285B (zh) * 2021-05-10 2022-05-24 深圳市展行生物有限公司 一种辅助诊断胃癌的方法及其使用的miRNA组合
CN113913516B (zh) * 2021-05-26 2023-08-29 东莞市松山湖中心医院(东莞市石龙人民医院、东莞市第三人民医院、东莞市心血管病研究所) hsa_circ_0006470作为靶点在制备miR-27b-3p的调节剂的应用
JP7406059B1 (ja) 2022-10-20 2023-12-27 防衛装備庁長官 急性ストレス評価用データの生成方法
WO2024229279A2 (en) * 2023-05-02 2024-11-07 Dana-Farber Cancer Institute, Inc. Use of circulating microrna profiles for identification of brca1 or brca2 mutations
CN118547069B (zh) * 2024-05-14 2025-08-22 北京热景生物技术股份有限公司 一种基于细胞外囊泡miRNA的胃癌诊断标志物及其应用
CN119580829A (zh) * 2024-11-25 2025-03-07 苏州大学 一种早期胃癌检测的标志物识别方法及诊断模型构建方法
CN119351558A (zh) * 2024-12-10 2025-01-24 西藏自治区人民政府驻成都办事处医院 一种检测胃癌的标志物、检测试剂盒及药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531052T3 (es) 2006-01-05 2015-03-10 Univ Ohio State Res Found Métodos y composiciones basados en microARN para el diagnóstico de cánceres de mama
AU2013245505B2 (en) * 2006-01-05 2016-06-23 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2257647B1 (en) 2008-02-28 2016-09-14 The Ohio State University Research Foundation Micro rna-based methods and compositions for the diagnosis of gastric cancer
US9765334B2 (en) 2008-06-01 2017-09-19 Rosetta Genomics, Ltd. Compositions and methods for prognosis of gastric cancer
CN101988059B (zh) 2009-07-30 2014-04-02 江苏命码生物科技有限公司 胃癌检测标记物及其检测试剂盒和生物芯片
WO2012010584A1 (en) 2010-07-20 2012-01-26 Febit Holding Gmbh Complex mirna sets as novel biomarkers for gastric cancer
US9939442B2 (en) * 2011-09-08 2018-04-10 The Regents Of The University Of California Salivary biomarkers for gastric cancer detection
JP2013085542A (ja) * 2011-10-21 2013-05-13 Sysmex Corp 胃癌の検出方法、胃癌の血液マーカーおよびその使用
GB201317887D0 (en) * 2013-10-09 2013-11-20 Reneuron Ltd Product
CN103773761B (zh) * 2014-01-14 2016-01-20 南京医科大学 检测胃癌的血清/血浆微小rna标志物及其应用
CN103937888B (zh) 2014-04-14 2016-08-17 上海交通大学 鉴别胃癌的血浆microRNA标志物的筛选与应用
SG10202011339RA (en) * 2014-08-07 2020-12-30 Agency Science Tech & Res Microrna biomarker for the diagnosis of gastric cancer

Also Published As

Publication number Publication date
JP2017525350A (ja) 2017-09-07
EP3744859B1 (en) 2025-05-07
JP2020141684A (ja) 2020-09-10
US20170233822A1 (en) 2017-08-17
JP7614735B2 (ja) 2025-01-16
KR102237960B1 (ko) 2021-04-08
JP2022188053A (ja) 2022-12-20
KR102604163B1 (ko) 2023-11-20
SG10202011339RA (en) 2020-12-30
JP7635186B2 (ja) 2025-02-25
EP3744859A2 (en) 2020-12-02
EP3177739A1 (en) 2017-06-14
CN107109470B (zh) 2020-09-15
KR20170035932A (ko) 2017-03-31
SG11201700944RA (en) 2017-03-30
US10767230B2 (en) 2020-09-08
KR20210057079A (ko) 2021-05-20
EP3177739A4 (en) 2018-05-02
WO2016022076A1 (en) 2016-02-11
EP4137586A1 (en) 2023-02-22
EP3177739B1 (en) 2019-10-23
CN107109470A (zh) 2017-08-29
EP3744859A3 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
JP7635186B2 (ja) 胃がん診断用のマイクロｒｎａバイオマーカー
CN107429295B (zh) 通过检测微小RNA(miRNA)的表达水平来确定患乳腺癌的风险的方法
AU2017246318A1 (en) Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
US20230227914A1 (en) Biomarkers of oral, pharyngeal and laryngeal cancers
CN103384829A (zh) 预测大肠直肠癌复发的生物标记
KR102096498B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로RNA-4732-5p 및 이의 용도
EP2657348B1 (en) Diagnostic miRNA profiles in multiple sclerosis
WO2023152568A2 (en) Compositions and methods for characterizing lung cancer
US20180251836A1 (en) Novel mirna biomarkers and use thereof
US20240254566A1 (en) Analysis method, kit, and detection device
KR102096499B1 (ko) 대장암 진단 또는 재발 예측을 위한 마이크로rna-3960 및 이의 용도
KR20190113108A (ko) 대장암 진단 또는 재발 예측을 위한 마이크로rna-3656 및 이의 용도
KR20190113100A (ko) 대장암 진단 또는 재발 예측을 위한 마이크로RNA-320c 및 이의 용도
CN105002177B (zh) 检测脂肪肉瘤的小rna指纹图谱及其应用
CN105368823B (zh) 小rna组成的指纹图谱在人胃肠道间质瘤中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200507

R150 Certificate of patent or registration of utility model

Ref document number: 6702935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250